Overview

Clinical Evaluation of Flortaucipir F 18

Status:
Completed
Trial end date:
2019-06-26
Target enrollment:
Participant gender:
Summary
This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.
Phase:
Phase 2
Details
Lead Sponsor:
Avid Radiopharmaceuticals